Michel Sadelain

7 ta ish

Memorial Sloan Kettering Cancer Center

1. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

   Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.102842

2. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

   Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

   MaqolaOAOchiq kirish20213 iqtibos

   ABIABI:AkademIndex/2026.other.102892

3. The Basic Principles of Chimeric Antigen Receptor Design

   Michel Sadelain, Renier J. Brentjens, Isabelle Rivière

   Sharh maqola20133 iqtibos

   ABIABI:AkademIndex/2026.other.340840

4. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

   Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.020461

5. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

   Hollie J. Pegram, James Lee, Erik Hayman +4

   MaqolaOAOchiq kirish20122 iqtibos

   ABIABI:AkademIndex/2026.other.102823

6. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells

   Esther Drent, Renée Poels, Ruud Ruiter +9

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.252116

7. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

   Melody Smith, Anqi Dai, Guido Ghilardi +46

   Maqola20222 iqtibos

   ABIABI:AkademIndex/2026.other.480531